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[ ]Ear ly  eradication therapy for Pseudomonas aeruginosa: impact 
of prior clinical status and choice of antibiotic regimen on 
eradication rates 
M. Denton 1, K. Brownlee 2, S. Conway 2'3, T. Lee 2, D. Peckham 3. 1Department 
of Microbiology, 2Regional Paediatric CF Unit, 3Regional Adult CF Unit, Leeds' 
Teaching Hospitals' NHS Trust, Leeds', UK 
Aims: Early eradication therapy may delay chronic infection with Pseudomonas 
aeruginosa in patients with CE We assessed the impact of prior clinical status 
(as determined by Leeds Criteria [1]) and antibiotic regimen on success rates of 
eradication therapy. 
Methods: The study was conducted at the Regional Paediatric CF Unit in Leeds, 
UK. We reviewed all episodes of eradication therapy between 1st January 2000 and 
31st December 2004. Patients were classified by Leeds Criteria as 'never', 'free' or 
'intermittent'. Success for each eradication therapy episode was determined using 
the Artimino consensus. Results were analyzed using Fisher's Exact test. 
Results: Data was complete on 223 episodes of eradication therapy in 118 patients. 
Fifty-five episodes were classified as 'never', 88 as 'free' and 80 as 'intermittent'. 
Success rates were 71%, 70% and 54% respectively. Rates were significantly higher 
in 'never'/'free' categories compared to intermittent (p 0.05/0.04 respectively). 
There were no statistically significant differences between regimens, but there was 
a trend towards higher rates by using intravenous antibiotics for two weeks (as 
compared to not using them) in conjunction with aerosolized and oral antibiotics 
for three months (74% versus 62%, p 0.1) 
Conclusion: Prior clinical status can be used to predict successful outcome of 
eradication therapy for early P aeruginosa colonization. The optimum regimen is 
unknown but the addition of two weeks of intravenous antibiotic therapy to existing 
'oral/aerosolized antibiotics for three months' protocols may improve success rates. 
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1~ Effect of TOBI ® on the eradication of Pseudomonas colonisation 
F. Marchetti 1 , L. Ronfani 1, J. Bua 1 , C. Braggion 2. The Collaborative Group of 
Italian Society for Cystic Fibrosis'. l Institute of Child Health Burlo Garofolo, 
Trieste; 2 CF Unit, Ospedale Civile Maggiore, Verona, Italy 
Aim: to investigate the effects of TOBI ® on the eradication of Pseudomonas 
aeruginosa (PA) first isolation in CE 
Methods: Our study is part of a TOBI ® post-marketing surveillance involving 
21 Italian CF centers. 621 CF patients were enrolled: 104 had a first PA infection, 
517 a chronic colonisation. All patients were followed-up at 1 year before, at the 
start, at 6 and 12 months of TOBI ® treatment. Eradication was defined as the 
absence of PA in 2 subsequent expectorate cultures after PA new isolation. 
Results: Out of 104, 100 patients completed the follow-up. 43%used only 
TOBI ®,57% TOBI ® in association with another antibiotic (95%oral ciprofloxacine). 
Overall 68% eradicated PA: 59 patients after 6 months (of whom 3 had a PA 
recurrent infection); 19 patients after 12 months. Univariate analyses howed 
a higher probability of eradication when TOBI ® was associated with another 
antibiotic (OR 5.2, 95%CI 1.4 19.2) and when macrolides were used in the 
12 months after TOBI ® start (OR 3.7, 95% CI 1.1 12.2); a lower probability with 
administration f intravenous (iv) antibiotics (OR 0.1, 95% CI 0.04 0.5), of DNAse 
(OR 0.1, 95% CI 0.03 0.4) and with hospitalization (OR 0.1, 95% CI 0.03 0.3). At 
multivariate analyses (on 43 patients) only the use of iv antibiotics was associated 
with PA eradication (OR 0.1, 95% CI 0.02 0.8). 
Conclusions: 68% of CF patients with first infection eradicated PA. The association 
between TOBI ® and another antibiotic may be more efficient although this associ- 
ation was present only at univariate analyses. The negative association between iv 
antibiotics and eradication may be attributed to TOBI ® inefficacy in patients with 
a more severe clinical condition. 
• Safety of inhaled tobramycin nebuliser solution for treatment of 
early Pseudomonas aeruginosa infection: First results from the 
ELITE study 
F. Ratjen 1, A. Munck 2, V Campello 3. For the ELITE study group. 1Hospital for 
Sick Children, Toronto, Canada; 2Hospital Robert Debre, Paris', France; 3 Chiron 
Corporation Ltd, Uxbridge, UK 
The primary objective of the ELITE study (EarLy Inhaled Tobramycin for Eradi- 
cation), an open-label, randomized, multi-centre study at 21 European CF centres, 
was to estimate duration of eradication of Pa following 28 or 56 days of twice- 
daily inhaled tobramycin ebuliser solution (TNS). Secondary objectives were 
to assess the proportion of subjects free from Pa 1 month after the end of 
treatment and safety profile of the two treatment arms. An unplanned interim safety 
evaluation was undertaken due to potentially relevant serum tobramycin levels 
in three subjects identified as AEs by the investigator. 90 patients (8 months to 
30 years old, 51% male) were enrolled at the time of analysis of which 66 were 
randomised to either 28 or 56 days of TNS. 13/34 subjects in the 28 d group 
were withdrawn early from the study compared to 7/32 subjects in the 56 d group. 
The majority of withdrawals were due to recurrence or lack of eradication of Pa. 
Four subjects experienced SAEs during the study, including two 28 d TNS subjects 
(severe constipation and moderate Stenotrophomonas infection) and two 56 d TNS 
subjects (severe gastroenteritis with exsiccosis and Varicella infection). Only the 
Stenotrophomonas infection was considered to be related to TNS treatment by the 
investigator. No changes in serum creatinine were observed. 4 patients had serum 
peak tobramycin levels >4 gg/mL of which one had a transient hearing loss on 
audiometry that had completely resolved after 4 weeks. In conclusion, these results 
demonstrate hat TNS 300rag twice daily for 28 and 56 days was safe and well 
tolerated by CF patients including patients <6 years of age. 
1• Treatment of intermittent Pseudomonas aeruginosa colonization 
with colistin and ciprofloxacin result in very low antibiotic 
resistance - 15 years follow up 
C.R. Hansen 1 , T. Pressler 2 , N. Hoiby 2 . 1 CF-Centre, Dept. of Microbiology, 2Dept. 
of Pediatrics, RigshosTitalet, Copenhagen, Denmark 
Methods: Since 1989, CF-patients with intermittent P aeruginosa colonization have 
been treated with inhaled colistin and oral ciprofloxacin (cipro). 146 CF-patients 
without chronic P aeruginosa-infection have been followed for 15 years (1501 
patient years). 36 patients became chronically infected and were excluded from the 
study at the time of chronic infection. 
Results: 1125 P aeruginosa isolates were studied. (7.7 isolates/patient): 966 non- 
mucoid, 159 mucoid strains. 618 courses of colistin and cipro, 121 courses of i.v. 
antibiotics and 61 courses of other combinations of inhaled and oral antibiotics 
were given (5.5 treatments/patient). 154 isolates found during treatment indicated 
treatment failure (14.7% of colistin/cipro treatments, 42.3% of other combinations). 
176 isolates were not treated found before early treatment was routine, or in 
patients with other chronic, G-negative infections. 
No colistin-resistant isolates were found. 45 cipro-resistant isolates were found 
(4% of all isolates) in 31 patients; 8 patients had recurrent growth of cipro-resistant 
isolates, while 23 patients had no more cipro-resistant isolates. 1st resistant strain 
occurred after a median of 24 weeks ofcipro-treatment (range 0 99), and a median 
of 1.7 years after first cipro-treatment (range 0 13.9). 40 isolates were non-mucoid 
(4.3% of all non-mucoid isolates) and 5 were mucoid (3.2% of all mucoid isolates). 
Percentage of cipro-resistant strains did not increase in the study period. 
Conclusion: Inhaled colsitin and oral cipro as treatment of intermittent P aerugi- 
nosa colonization in CF-patients can lead to a small percentage of cipro-resistant 
isolates, which tend to occur after several weeks of treatment. 
